Clinically benign, histologically malignant, recurrent cutaneous T-cell lymphoproliferative disorder characterized by an infiltration of large atypical cells surrounded by inflammatory cells. The atypical cells resemble REED-STERNBERG CELLS of HODGKIN DISEASE or the malignant cells of CUTANEOUS T-CELL LYMPHOMA. In some cases, lymphomatoid papulosis progresses to lymphomatous conditions including MYCOSIS FUNGOIDES; HODGKIN DISEASE; CUTANEOUS T-CELL LYMPHOMA; or ANAPLASTIC LARGE-CELL LYMPHOMA.
Variously described as a vasculopathy, endovasculitis, or occlusive arteriopathy, this condition occurs in a benign cutaneous form and a lethal multiorgan systemic variant. It is characterized by a narrowing and occlusion of the lumen of small to medium-sized blood vessels, leading to ischemia and infarction in the involved organ systems. The etiology and pathophysiology are unknown.
A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. They are found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.
A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.
A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called "hallmark" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.
A group of dermatoses with distinct morphologic features. The primary lesion is most commonly a papule, usually erythematous, with a variable degree of scaling on the surface. Plaques form through the coalescing of primary lesions.
Anaplastic lymphoma of the skin which develops as a primary neoplasm expressing the CD30 ANTIGEN. It is characterized by solitary nodules or ulcerated tumors.
The use of ultraviolet electromagnetic radiation in the treatment of disease, usually of the skin. This is the part of the sun's spectrum that causes sunburn and tanning. Ultraviolet A, used in PUVA, is closer to visible light and less damaging than Ultraviolet B, which is ionizing.
A name originally applied to a group of skin diseases characterized by the formation of fine, branny scales, but now used only with a modifier. (Dorland, 27th ed)
'Skin diseases' is a broad term for various conditions affecting the skin, including inflammatory disorders, infections, benign and malignant tumors, congenital abnormalities, and degenerative diseases, which can cause symptoms such as rashes, discoloration, eruptions, lesions, itching, or pain.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
Tumors or cancer of the SKIN.
Drugs used to treat or prevent skin disorders or for the routine care of skin.
A persistent progressive non-elevated red scaly or crusted plaque which is due to an intradermal carcinoma and is potentially malignant. Atypical squamous cells proliferate through the whole thickness of the epidermis. The lesions may occur anywhere on the skin surface or on mucosal surfaces. The cause most frequently found is trivalent arsenic compounds. Freezing, cauterization or diathermy coagulation is often effective. (From Rook et al., Textbook of Dermatology, 4th ed, pp2428-9)
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development.

A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. (1/27)

Spontaneous regression of skin lesions is characteristic of lymphomatoid papulosis (LyP), a clonal cutaneous lymphoproliferative disorder. A minority of LyP patients progress to anaplastic large cell lymphoma (ALCL) in which skin lesions no longer regress and extracutaneous dissemination often occurs. In 1 such case, we developed a tumor cell line, JK cells, and show that these cells are resistant to the growth inhibitory effects of transforming growth factor beta (TGF-beta) due to the loss of cell surface expression of the TGF-beta type I receptor (TbetaR-I). Reverse transcriptase-polymerase chain reaction (RT-PCR) and sequencing of JK cell TbetaR-I cDNA clones identified a deletion that spanned the last 178 bp of exon 1, including the initiating methionine. Hybridization of a radiolabeled fragment internal to the deletion was detected in the genomes of TGF-beta-responsive cells, but not in JK cells, indicating that they contain no wild-type TbetaR-I gene. PCR primers that flanked the deleted TbetaR-I region amplified a single band from JK cell genomic DNA that lacked the last 178 bp of exon 1 and all of the approximately 5 kb of intron 1. This JK cell-specific genomic TbetaR-I PCR product was distinct from products amplified from TGF-beta-responsive cells and was also readily detected in tumor biopsies obtained before the establishment of the JK cell line. Our results identify the first inactivating mutation in TbetaR-I gene in a human lymphoma that renders it insensitive to growth inhibition by TGF-beta.  (+info)

Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common clonal T-cell origin. (2/27)

Lymphomatoid papulosis (LyP) represents an intriguing cutaneous T-cell lymphoproliferative disorder with a histologic appearance resembling malignant lymphoma. This finding strongly contrasts with the benign clinical course of the disease. However, in 10% to 20% of cases, LyP can precede, coexist with, or follow malignant lymphoma. In these cases, the same T-cell population has been shown to be present in the LyP as well as in the associated lymphoma. In most LyP cases, there is-despite the sometimes extremely long course of the disease-no evolution of a secondary lymphoma. The investigation of these uncomplicated LyP cases for the presence of clonal T-cell receptor rearrangements has produced heterogeneous results. This might be explained by biologic or technical reasons arising from analyzing whole tissue DNA extracts. To definitively clarify whether the large atypical CD30(+) cells in LyP without associated lymphoma all belong to the same clone or represent individually rearranged T cells, we analyzed the T-cell receptor-gamma rearrangements of single CD30+ as well as of single CD30- cells isolated from 14 LyP lesions of 11 patients. By using this approach we could demonstrate that the CD30+ cells represent members of a single T-cell clone in all LyP cases. Moreover, in 3 patients the same CD30+ cell clone was found in anatomically and temporally separate lesions. In contrast, with only a few exceptions, the CD30- cells were polyclonal in all instances and unrelated to the CD30+ cell clone. Our results demonstrate that LyP unequivocally represents a monoclonal T-cell disorder of CD30+ cells in all instances.  (+info)

Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease. (3/27)

Recent studies demonstrated that Hodgkin/Reed-Sternberg (H/RS) cells in Hodgkin's disease (HD) express thymus and activation-regulated chemokine (TARC), whereas reactive lymphocytes surrounding H/RS cells express its ligand, CC-chemokine receptor 4 (CCR4). Because in vitro studies showed that CCR4 expression is a marker for lymphocytes bearing a T-helper 2 (Th2) phenotype, it was suggested that expression of TARC is a new immune escape mechanism in HD. To find out whether this mechanism might also be operative in CD30+ malignant lymphomas other than HD, TARC and CCR4 expression was investigated by immunohistochemistry on paraffin and frozen-tissue sections of 39 nodal CD30+ anaplastic large cell lymphomas (ALCL), including 27 ALK-negative and 12 ALK-positive ALCL, 25 primary cutaneous CD30+ ALCL, including 11 patients with lymphomatoid papulosis, and 31 cases of HD. TARC was expressed by the neoplastic cells in 12/27 (44%) nodal ALK-negative ALCL and all cases of classic HD, but not in nodal ALK-positive ALCL (0/12) and only rarely in primary cutaneous CD30+ ALCL (3/25). In contrast, CCR4 was expressed by the neoplastic cells in 9/9 cutaneous CD30+ ALCL, and in 9/15 (60%) nodal ALK-negative ALCL, but only in 1/4 (25%) nodal ALK-positive ALCL and not by the H/RS cells in HD (0/8). Apart from three cases of HD showing 10 to 15% CCR4-positive lymphocytes surrounding TARC-positive H/RS cells, CCR4-positive reactive T cells were few (<5%) in all other cases studied. Our results demonstrate a differential expression of TARC and CCR4 in different types of CD30+ malignant lymphomas. The small number of CCR4-positive reactive T cells in most cases studied argues against an important role of TARC expression in the evasion of antitumor responses.  (+info)

Granulomatous eccrinotropic lymphomatoid papulosis. (4/27)

We describe 9 patients with a novel variant of lymphomatoid papulosis characterized by prominent localization of the infiltrate around the eccrine coil, resulting in nodular expansion of the coil accompanied by variable granulomatous inflammation. Light microscopy, immunohistochemical analysis using antibodies to CD2, CD3, CD4, CD5, CD7, CD8, and CD30 in 6 cases, and polymerase chain reaction--single-stranded conformational polymorphism analysis for T-cell receptor gamma chain gene rearrangement in 5 cases revealed 2 cytomorphologic patterns (large cell dominant with polymorphous inflammation, small cell lymphocyte--rich with an inconspicuous large cell component [phenotypes, CD30+/CD3+/CD4+/CD7-for large atypical cells; reactive for small lymphocytes]) and clonal restriction in 4 and polyclonality in 1 of the lymphocyte-dominant cases. During an average 6-year follow-up, no lymphomas developed. Recognition of this variant is important--accentuation of the infiltrate around the eccrine coil and cutaneous nerves, presence of granulomatous inflammation, dominance of small lymphocytes in the dermis, and variable extension into the panniculus may lead to diagnostic confusion with entities such as discoid lupus erythematosus, Jessner lymphocytic infiltrate of skin, subcutaneous T-cell lymphoma, and persistent arthropod bite reaction. Our findings suggest that pruritus, a younger age at diagnosis, and a more indolent course are defining clinical features.  (+info)

Bone marrow precursor of extranodal T-cell lymphoma. (5/27)

The development of extranodal lymphomas is thought to be initiated by the transformation event in peripheral organs. Lymphomatoid papulosis (LyP) is a low-grade cutaneous lymphoma and may progress into the cutaneous anaplastic lymphoma. We identified 2 patients who 3 and 4 years before the development of LyP were treated for an unrelated malignancy (Burkitt lymphoma and small-cell B-cell lymphoma). We analyzed the T-cell receptor (TCR) gene rearrangement pattern in their skin, blood, and bone marrow, including the archival bone marrow sampled years before the development of clinically evident LyP. In all samples we detected the unique monoclonal TCR rearrangements. This observation suggests that the initial malignant transformation in LyP occurred in bone marrow and not, as could be supposed, in the skin.  (+info)

Lymphomatoid papulosis associated with recurrent cutaneous T-cell lymphoma. (6/27)

INTRODUCTION: Lymphomatoid papulosis is a chronic benign disease which may be associated with malignant lymphomas. This case illustrates the relapsing and remitting nature of both lymphomatoid papulosis and its potential of developing cutaneous T-cell lymphoma and narrow-band ultraviolet B (NB-UVB) phototherapy as a new modality of treatment of early-stage mycosis fungoides in these patients. CLINICAL PICTURE: A 44-year-old woman has had recurrent crops of papules and nodules of lymphomatoid papulosis on the limbs for 15 years. Histological features are consistent with the type B lesions of lymphomatoid papulosis. Eight years after the initial onset of these lesions she developed cutaneous T-cell lymphoma (mycosis fungoides). Since then, she has had recurrence of mycosis fungoides following the cessation of phototherapy, but had no evidence of systemic involvement. TREATMENT: The lesions of lymphomatoid papulosis responded to intermittent courses of oral methotrexate. Mycosis fungoides was treated with oral psoralen and ultraviolet A phototherapy with good response. Unfortunately, the lesions relapsed, whenever phototherapy was discontinued. The most recent recurrence of mycosis fungoides was treated with NB-UVB therapy. OUTCOME: The papules of lymphomatoid papulosis continue to appear but she remains free of lesions of mycosis fungoides, 10 months after cessation of NB-UVB therapy. CONCLUSION: Long-term surveillance is essential in all cases of lymphomatoid papulosis as accurate predictors for the development of malignant lymphoma in these individuals are still lacking.  (+info)

Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. (7/27)

c-Kit receptor (CD117) is expressed by erythroid, megakaryocytic, and myeloid precursors and mature mast cells and has been reported to be expressed in CD30+ lymphomas such as Hodgkin's disease and anaplastic large-cell lymphoma. Imatinib mesylate, a well-established inhibitor of bcr-abl tyrosine kinase, and currently used for the treatment of patients with chronic myeloid leukemia, also inhibits c-kit receptor kinase activity. In view of the possible use of imatinib as experimental therapy for patients with c-kit-positive tumors, we assessed c-kit expression in CD30+ cell lines and lymphomas. The cell lines were assessed using multiple methods (RT-PCR, flow cytometry, and Western blot). c-Kit expression was also immunohistochemically assessed in 168 CD30+ lymphomas including 87 classical Hodgkin's disease, 63 anaplastic large-cell lymphoma, and 15 cutaneous anaplastic large-cell lymphoma. We also studied 18 cases of lymphomatoid papulosis, a CD30+ lesion closely related to cutaneous anaplastic large-cell lymphoma. Neither c-kit mRNA nor protein was detected in any of the cell lines assessed. Furthermore, treatment with imatinib did not inhibit proliferation of cell lines in vitro. Using immunohistochemistry, only one of 183 (0.5%) lesions was positive for c-kit, the positive case being an ALK-negative anaplastic large-cell lymphoma. Our data demonstrate that expression of c-kit receptor is exceedingly rare among CD30+ lymphomas and lymphomatoid papulosis, suggesting that c-kit receptor is unlikely to be an appropriate target for therapeutic options such as imatinib in patients with these tumors.  (+info)

Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders. (8/27)

Lymphomatoid papulosis is a preneoplastic cutaneous lymphoproliferative disorder characterized by overexpression of CD30, a member of the tumor necrosis factor receptor superfamily. CD30 signaling is known to have an effect on the growth and survival of lymphoid cells. Therefore, we hypothesized that the development of lymphomatoid papulosis and progression to an associated neoplasm such as cutaneous and systemic anaplastic large cell lymphoma may reflect an underlying genetic defect. In this study, we determined that two allelic forms of the CD30 promoter microsatellite repressive element, designated 30M377 and 30M362, are associated with the development of lymphomatoid papulosis and CD30+ lymphomas in lymphomatoid papulosis patients, respectively. These findings suggest that allele-specific differences in the control of CD30 transcription may determine the pathogenesis of the spectrum of CD30+ cutaneous lymphoproliferative disorders.  (+info)

Lymphomatoid papulosis (LyP) is a rare, chronic skin disorder characterized by recurrent, self-healing papules and nodules. It is considered a low-grade T-cell lymphoma, but it is distinct from other cutaneous lymphomas due to its benign clinical course and lack of systemic involvement in most cases. The lesions typically undergo cycles of appearing, ulcerating, and then resolving over a period of several weeks to months, only to recur elsewhere on the body.

Histologically, LyP is characterized by an inflammatory infiltrate composed of small lymphocytes, histiocytes, eosinophils, and atypical large cells with Reed-Sternberg-like morphology. The condition is often associated with other lymphoproliferative disorders, such as mycosis fungoides or Hodgkin's lymphoma, and it is important to monitor patients closely for signs of progression to more aggressive lymphomas.

The exact cause of LyP remains unclear, but it is thought to involve an abnormal immune response and genetic factors. Treatment options include topical therapies, phototherapy, and systemic medications such as methotrexate or retinoids. However, the choice of treatment depends on the severity and extent of the disease, as well as the individual patient's needs and preferences.

Malignant atrophic papulosis (MAP), also known as Kohlmeier-Degos disease, is a rare and progressive cutaneous vasculopathy of unknown etiology. It is characterized by the development of porcelain-white atrophic macules, which evolve into papules with a central necrotic depression or ulceration, surrounded by an erythematous halo. The lesions typically appear on the trunk and extremities, but may also affect mucous membranes, gastrointestinal tract, and other organs.

MAP is considered to be a chronic inflammatory disorder that affects small-sized blood vessels, leading to tissue ischemia and necrosis. The disease can have a variable clinical course, ranging from self-limited cutaneous involvement to systemic manifestations with potentially life-threatening complications.

The diagnosis of MAP is based on the clinical presentation, histopathological findings, and exclusion of other similar conditions. Treatment options for MAP are limited, and there is no cure for this disease. The management typically involves a multidisciplinary approach to address the various organ manifestations and prevent complications.

CD30 is a type of protein found on the surface of some cells in the human body, including certain immune cells like T-cells and B-cells. It is also known as Ki-1 antigen. CD30 plays a role in the regulation of the immune response and can be activated during an immune reaction.

CD30 is often used as a marker to identify certain types of cancer, such as Hodgkin lymphoma and anaplastic large cell lymphoma. These cancers are characterized by the presence of cells that express CD30 on their surface.

CD30 antigens can be targeted with immunotherapy, such as monoclonal antibodies, to treat these types of cancer. For example, brentuximab vedotin is a monoclonal antibody that targets CD30 and has been approved for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.

Cutaneous T-cell lymphoma (CTCL) is a type of cancer that affects T-cells, a specific group of white blood cells called lymphocytes. These cells play a crucial role in the body's immune system and help protect against infection and disease. In CTCL, the T-cells become malignant and accumulate in the skin, leading to various skin symptoms and lesions.

CTCL is a subtype of non-Hodgkin lymphoma (NHL), which refers to a group of cancers that originate from lymphocytes. Within NHL, CTCL is categorized as a type of extranodal lymphoma since it primarily involves organs or tissues outside the lymphatic system, in this case, the skin.

The two most common subtypes of CTCL are mycosis fungoides and Sézary syndrome:

1. Mycosis fungoides (MF): This is the more prevalent form of CTCL, characterized by patches, plaques, or tumors on the skin. The lesions may be scaly, itchy, or change in size, shape, and color over time. MF usually progresses slowly, with early-stage disease often confined to the skin for several years before spreading to lymph nodes or other organs.
2. Sézary syndrome (SS): This is a more aggressive form of CTCL that involves not only the skin but also the blood and lymph nodes. SS is characterized by the presence of malignant T-cells, known as Sézary cells, in the peripheral blood. Patients with SS typically have generalized erythroderma (reddening and scaling of the entire body), pruritus (severe itching), lymphadenopathy (swollen lymph nodes), and alopecia (hair loss).

The diagnosis of CTCL usually involves a combination of clinical examination, skin biopsy, and immunophenotyping to identify the malignant T-cells. Treatment options depend on the stage and subtype of the disease and may include topical therapies, phototherapy, systemic medications, or targeted therapies.

Mycosis fungoides is the most common type of cutaneous T-cell lymphoma (CTCL), a rare cancer that affects the skin's immune system. It is characterized by the infiltration of malignant CD4+ T-lymphocytes into the skin, leading to the formation of patches, plaques, and tumors. The disease typically progresses slowly over many years, often starting with scaly, itchy rashes that can be mistaken for eczema or psoriasis. As the disease advances, tumors may form, and the lymphoma may spread to other organs, such as the lymph nodes, lungs, or spleen. Mycosis fungoides is not contagious and cannot be spread from person to person. The exact cause of mycosis fungoides is unknown, but it is thought to result from a combination of genetic, environmental, and immune system factors.

Large cell anaplastic lymphoma is a type of cancer that starts in white blood cells called lymphocytes, which are part of the body's immune system. It is classified as a type of non-Hodgkin lymphoma (NHL).

Anaplastic large cell lymphoma (ALCL) is a subtype of NHL characterized by the presence of large cancer cells that look abnormal under a microscope. These cells are called "anaplastic" because they lack many of the usual features of mature lymphocytes.

ALCL can occur in many different parts of the body, including the lymph nodes, skin, lungs, and soft tissues. It is typically an aggressive form of NHL that grows and spreads quickly.

ALCL is further divided into two main subtypes based on the presence or absence of a genetic abnormality involving a protein called ALK (anaplastic lymphoma kinase). ALK-positive ALCL tends to occur in younger patients and has a better prognosis than ALK-negative ALCL.

Treatment for large cell anaplastic lymphoma typically involves chemotherapy, radiation therapy, and/or immunotherapy, depending on the stage and location of the cancer. In some cases, stem cell transplantation may also be recommended.

Papulosquamous skin diseases are a group of chronic inflammatory disorders of the skin characterized by the development of papules (small, solid, often conical bump) and scales. These diseases include psoriasis, lichen planus, and seborrheic dermatitis among others. The skin lesions in these conditions are often red, scaly, and may be pruritic (itchy). They can vary in severity and distribution, and can have a significant impact on a person's quality of life. The exact cause of these diseases is not fully understood, but they are believed to involve an abnormal immune response and genetic factors. Treatment typically involves a combination of topical therapies, phototherapy, and systemic medications.

Primary cutaneous lymphomas are a group of non-Hodgkin lymphomas that primarily involve the skin. The primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare type of primary cutaneous lymphoma, accounting for less than 1% of all cutaneous lymphomas.

PCALCL is characterized by the presence of large, atypical cells called Reed-Sternberg cells or their variants, which are typically found in classical Hodgkin lymphoma. However, in PCALCL, these cells are primarily found in the skin without evidence of systemic involvement at the time of diagnosis.

PCALCL usually presents as one or more reddish-purple nodules or tumors on the skin that may ulcerate and can be tender or pruritic. The most common sites of involvement include the head, neck, trunk, and upper extremities.

The etiology of PCALCL is unknown, but it has been associated with immune suppression, including organ transplantation and human immunodeficiency virus (HIV) infection.

PCALCL is generally an indolent disease with a good prognosis, and most cases can be managed with local therapies such as surgical excision, radiation therapy, or intralesional injections of chemotherapy or corticosteroids. However, some cases may progress or recur, requiring systemic therapy with chemotherapy, immunotherapy, or targeted agents.

Overall, PCALCL is a rare and distinct type of primary cutaneous lymphoma that requires careful clinical evaluation and management by a multidisciplinary team of dermatologists, pathologists, and oncologists.

Ultraviolet (UV) therapy, also known as phototherapy, is a medical treatment that uses ultraviolet light to treat various skin conditions. The UV light can be delivered through natural sunlight or artificial sources, such as specialized lamps or lasers.

In medical settings, controlled doses of UV light are used to target specific areas of the skin. The most common type of UV therapy is narrowband UVB (NB-UVB) phototherapy, which uses a specific wavelength of UVB light to treat conditions such as psoriasis, eczema, vitiligo, and dermatitis.

The goal of UV therapy is to reduce inflammation, slow skin cell growth, and improve the overall appearance of the skin. It is important to note that while UV therapy can be effective in treating certain skin conditions, it also carries risks such as skin aging and an increased risk of skin cancer. Therefore, it should only be administered under the supervision of a qualified healthcare professional.

Pityriasis is a general term used to describe a group of skin conditions characterized by scaling. It includes several specific types, the most common being Pityriasis rosea and Pityriasis simplex capillitii (also known as dandruff).

1. Pityriasis rosea: This is a temporary skin rash that often begins with a single, round, scaly patch on the chest, abdomen, or back. A few days to weeks later, more patches appear. These patches are oval and scaly, and they may be pink, red, or tan. The rash usually lasts about 6-8 weeks.

2. Pityriasis simplex capillitii: This is a very common condition characterized by flaking or scaling of the scalp, which is often referred to as dandruff.

The term "pityriasis" comes from the Greek word "pitýrios," which means "bran."

Skin diseases, also known as dermatological conditions, refer to any medical condition that affects the skin, which is the largest organ of the human body. These diseases can affect the skin's function, appearance, or overall health. They can be caused by various factors, including genetics, infections, allergies, environmental factors, and aging.

Skin diseases can present in many different forms, such as rashes, blisters, sores, discolorations, growths, or changes in texture. Some common examples of skin diseases include acne, eczema, psoriasis, dermatitis, fungal infections, viral infections, bacterial infections, and skin cancer.

The symptoms and severity of skin diseases can vary widely depending on the specific condition and individual factors. Some skin diseases are mild and can be treated with over-the-counter medications or topical creams, while others may require more intensive treatments such as prescription medications, light therapy, or even surgery.

It is important to seek medical attention if you experience any unusual or persistent changes in your skin, as some skin diseases can be serious or indicative of other underlying health conditions. A dermatologist is a medical doctor who specializes in the diagnosis and treatment of skin diseases.

Lymphoproliferative disorders (LPDs) are a group of diseases characterized by the excessive proliferation of lymphoid cells, which are crucial components of the immune system. These disorders can arise from both B-cells and T-cells, leading to various clinical manifestations ranging from benign to malignant conditions.

LPDs can be broadly classified into reactive and neoplastic categories:

1. Reactive Lymphoproliferative Disorders: These are typically triggered by infections, autoimmune diseases, or immunodeficiency states. They involve an exaggerated response of the immune system leading to the excessive proliferation of lymphoid cells. Examples include:
* Infectious mononucleosis (IM) caused by Epstein-Barr virus (EBV)
* Lymph node enlargement due to various infections or autoimmune disorders
* Post-transplant lymphoproliferative disorder (PTLD), which occurs in the context of immunosuppression following organ transplantation
2. Neoplastic Lymphoproliferative Disorders: These are malignant conditions characterized by uncontrolled growth and accumulation of abnormal lymphoid cells, leading to the formation of tumors. They can be further classified into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Examples include:
* Hodgkin lymphoma (HL): Classical HL and nodular lymphocyte-predominant HL
* Non-Hodgkin lymphoma (NHL): Various subtypes, such as diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma

It is important to note that the distinction between reactive and neoplastic LPDs can sometimes be challenging, requiring careful clinical, histopathological, immunophenotypic, and molecular evaluations. Proper diagnosis and classification of LPDs are crucial for determining appropriate treatment strategies and predicting patient outcomes.

Skin neoplasms refer to abnormal growths or tumors in the skin that can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled multiplication of skin cells, which can form various types of lesions. These growths may appear as lumps, bumps, sores, patches, or discolored areas on the skin.

Benign skin neoplasms include conditions such as moles, warts, and seborrheic keratoses, while malignant skin neoplasms are primarily classified into melanoma, squamous cell carcinoma, and basal cell carcinoma. These three types of cancerous skin growths are collectively known as non-melanoma skin cancers (NMSCs). Melanoma is the most aggressive and dangerous form of skin cancer, while NMSCs tend to be less invasive but more common.

It's essential to monitor any changes in existing skin lesions or the appearance of new growths and consult a healthcare professional for proper evaluation and treatment if needed.

Dermatologic agents are medications, chemicals, or other substances that are applied to the skin (dermis) for therapeutic or cosmetic purposes. They can be used to treat various skin conditions such as acne, eczema, psoriasis, fungal infections, and wounds. Dermatologic agents include topical corticosteroids, antibiotics, antifungals, retinoids, benzoyl peroxide, salicylic acid, and many others. They can come in various forms such as creams, ointments, gels, lotions, solutions, and patches. It is important to follow the instructions for use carefully to ensure safety and effectiveness.

Bowen's disease is a skin condition that is characterized by the growth of abnormal cells on the outermost layer of the skin (the epidermis). It is also known as squamous cell carcinoma in situ. The affected area often appears as a red, scaly patch or plaque, and it can develop anywhere on the body, but it is most commonly found on sun-exposed areas such as the face, hands, arms, and legs.

Bowen's disease is considered a precancerous condition because there is a risk that the abnormal cells could eventually develop into invasive squamous cell carcinoma, a type of skin cancer. However, not all cases of Bowen's disease will progress to cancer, and some may remain stable or even regress on their own.

The exact cause of Bowen's disease is not known, but it is thought to be associated with exposure to certain chemicals, radiation, and human papillomavirus (HPV) infection. Treatment options for Bowen's disease include cryotherapy, topical chemotherapy, photodynamic therapy, curettage and electrodessication, and surgical excision. Regular follow-up with a healthcare provider is recommended to monitor the condition and ensure that it does not progress to cancer.

Hodgkin disease, also known as Hodgkin lymphoma, is a type of cancer that originates in the white blood cells called lymphocytes. It typically affects the lymphatic system, which is a network of vessels and glands spread throughout the body. The disease is characterized by the presence of a specific type of abnormal cell, known as a Reed-Sternberg cell, within the affected lymph nodes.

The symptoms of Hodgkin disease may include painless swelling of the lymph nodes in the neck, armpits, or groin; fever; night sweats; weight loss; and fatigue. The exact cause of Hodgkin disease is unknown, but it is thought to involve a combination of genetic, environmental, and infectious factors.

Hodgkin disease is typically treated with a combination of chemotherapy, radiation therapy, and/or immunotherapy, depending on the stage and extent of the disease. With appropriate treatment, the prognosis for Hodgkin disease is generally very good, with a high cure rate. However, long-term side effects of treatment may include an increased risk of secondary cancers and other health problems.

"Gene rearrangement" is a process that involves the alteration of the order, orientation, or copy number of genes or gene segments within an organism's genome. This natural mechanism plays a crucial role in generating diversity and specificity in the immune system, particularly in vertebrates.

In the context of the immune system, gene rearrangement occurs during the development of B-cells and T-cells, which are responsible for adaptive immunity. The process involves breaking and rejoining DNA segments that encode antigen recognition sites, resulting in a unique combination of gene segments and creating a vast array of possible antigen receptors.

There are two main types of gene rearrangement:

1. V(D)J recombination: This process occurs in both B-cells and T-cells. It involves the recombination of variable (V), diversity (D), and joining (J) gene segments to form a functional antigen receptor gene. In humans, there are multiple copies of V, D, and J segments for each antigen receptor gene, allowing for a vast number of possible combinations.
2. Class switch recombination: This process occurs only in mature B-cells after antigen exposure. It involves the replacement of the constant (C) region of the immunoglobulin heavy chain gene with another C region, resulting in the production of different isotypes of antibodies (IgG, IgA, or IgE) that have distinct effector functions while maintaining the same antigen specificity.

These processes contribute to the generation of a diverse repertoire of antigen receptors, allowing the immune system to recognize and respond effectively to a wide range of pathogens.

... (LyP) is a rare skin disorder. The overall prevalence rate of lymphomatoid papulosis is estimated at at ... Magro CM, Crowson AN, Morrison C, Merati K, Porcu P, Wright ED (April 2006). "CD8+ lymphomatoid papulosis and its differential ... Dalle S, Balme B, Thomas L (2006). "Lymphomatoid papulosis localized to the face". Dermatol. Online J. 12 (3): 9. doi:10.5070/ ... El Shabrawi-Caelen L, Kerl H, Cerroni L (April 2004). "Lymphomatoid papulosis: reappraisal of clinicopathologic presentation ...
... and Hodgkin cell specific antigen on atypical cells in lymphomatoid papulosis. 2nd Internat. Conference on Malignant Lymphoma. ... and Characterization of CD 30-positive infiltrates in lymphomatoid papulosis and related disorders (Lugano 1984). Burg's ...
... and in patients with lymphomatoid papulosis.: 738 Cutaneous T-cell lymphoma CD30+ cutaneous T-cell lymphoma Skin lesion List of ...
Leukemia cutis Lymphoma cutis Lymphomatoid granulomatosis Lymphomatoid papulosis Malignant histiocytosis (histiocytic medullary ... Malignant atrophic papulosis (Degos' disease) Marshall-White syndrome Meige lymphedema Microscopic polyangiitis (microscopic ... B virus infection Boston exanthem disease Bovine papular stomatitis Bowenoid papulosis Buffalopox Butcher's wart Chikungunya ...
Mycosis fungoides Sézary syndrome Primary cutaneous CD30-positive T-cell lymphoproliferative disorders Lymphomatoid papulosis ... 2 Lymphomatoid granulomatosis, grade 3 Primary mediastinal (thymic) large B-cell lymphoma Intravascular large B-cell lymphoma ... mucocutaneous ulcer DLBCL associated with chronic inflammation Fibrin-associated diffuse large B-cell lymphoma Lymphomatoid ...
EBV+ LG may progress to or become complicated by the non-malignant skin disease, lymphomatoid papulosis, or a second lymphoid ... EBV+ lymphomatoid granulomatosis (EBV+ LG, also termed lymphomatoid granulomatosis [LG]) is a rare disease that involves ... Sigamani E, Chandramohan J, Nair S, Chacko G, Thomas M, Mathew LG, Pulimood S, Manipadam MT (2018). "Lymphomatoid ... Roschewski M, Wilson WH (2012). "Lymphomatoid granulomatosis". Cancer Journal (Sudbury, Mass.). 18 (5): 469-74. doi:10.1097/PPO ...
Lymphomatoid papulosis Primary cutaneous anaplastic large cell lymphoma Primary cutaneous CD30+ large T-cell lymphoma M9719/3 ... Angiocentric immunoproliferative lesion LYmphoid granulomatosis Lymphomatoid granulomatosis M9767/1 Angioimmunoblastic ...
... lymphomatoid papulosis, chemical burn, Toxicodendron dermatitis, squamous cell carcinoma, neoplasia, localized vasculitis, ...
... follicular Lymphoma Lymphomatoid granulomatosis Lymphomatoid Papulosis (LyP) Lymphomatous thyroiditis Lymphosarcoma Lynch-Lee- ... lymphomatoid papulosis) Lysine alpha-ketoglutarate reductase deficiency Lysinuric protein intolerance Lysosomal alpha-D- ...
Pityriasis lichenoides Pityriasis lichenoides chronica Pityriasis lichenoides et varioliformis acuta Lymphomatoid papulosis ...
... lymphomatoid papulosis MeSH C17.800.859.600.675 - pityriasis rosea MeSH C17.800.859.600.685 - pityriasis rubra pilaris MeSH ... lymphomatoid papulosis MeSH C17.800.859.600 - pityriasis MeSH C17.800.859.600.650 - pityriasis lichenoides MeSH C17.800.859.600 ... lymphomatoid papulosis MeSH C17.800.859.575 - parapsoriasis MeSH C17.800.859.575.650 - pityriasis lichenoides MeSH C17.800. ...
CD30-positive T cell lymphoproliferative disorders Primary cutaneous anaplastic large cell lymphoma Lymphomatoid papulosis ... and lymphomatoid gastropathy, a disease wherein these cells' infiltrative lesions are limited to the stomach. These diseases do ... not otherwise specified Lymphomatoid granulomatosis Primary mediastinal (thymic) large B-cell lymphoma Intravascular large B- ...
... common lymphoma in the category of Cutaneous T cell lymphoma cutaneous T cell lymphomas that includes lymphomatoid papulosis, ...
Pagetoid reticulosis Sézary syndrome Granulomatous slack skin Lymphomatoid papulosis Pityriasis lichenoides chronica Pityriasis ...
Lymphomatoid papulosis (LyP) is a rare skin disorder. The overall prevalence rate of lymphomatoid papulosis is estimated at at ... Magro CM, Crowson AN, Morrison C, Merati K, Porcu P, Wright ED (April 2006). "CD8+ lymphomatoid papulosis and its differential ... Dalle S, Balme B, Thomas L (2006). "Lymphomatoid papulosis localized to the face". Dermatol. Online J. 12 (3): 9. doi:10.5070/ ... El Shabrawi-Caelen L, Kerl H, Cerroni L (April 2004). "Lymphomatoid papulosis: reappraisal of clinicopathologic presentation ...
Lymphomatoid papulosis (LyP) is a chronic papulonecrotic or papulonodular skin disease with histologic features suggestive of a ... The etiology of lymphomatoid papulosis is unknown. Debate persists over whether (1) lymphomatoid papulosis is a benign chronic ... encoded search term (Lymphomatoid Papulosis) and Lymphomatoid Papulosis What to Read Next on Medscape ... duration on the left lateral thigh of a 57-year-old man with a 5-year history of lymphomatoid papulosis. The lymphomatoid ...
... in Child. Print Images (39) Contributors: Vincent Hensperger, Amy Kalowitz Bieber MD, Belinda Tan MD, ... Lymphomatoid papulosis (LyP) is a recurrent, chronic, self-healing eruption that exists on a continuum with primary cutaneous ...
Lymphomatoid papulosis. Dermatologica 1972; 144: 65-74.. 8. Thomas GJ, Conejo-Mir JS, Ruiz AP et al. Lymphomatoid papulosis in ... Lymphomatoid papulosis in children. J Am Acad Dermatol 1995; 33: 741-8.. 5. Kagaya M, Kondo S, Kamada A et al. Localized ... Regional lymphomatoid papulosis: a report of four cases. Br J Dermatol 1999; 141: 1125-8.. 7. Thomsen K, Hjort G, Svendsen D. ... Lymphomatoid papulosis localized to the face. Stéphane Dalle, Brigitte Balme, and Luc Thomas Dermatology Online Journal 12 (3 ...
A variant of lymphomatoid papulosis characterized by an epidermotropic infiltrate composed of small atypical cerebriform-like ... Type B lymphomatoid papulosis.. Bouhamidi A, Hassam B. Pan Afr Med J 2018;30:138. Epub 2018 Jun 18 doi: 10.11604/pamj.2018.30. ... A variant of lymphomatoid papulosis characterized by an epidermotropic infiltrate composed of small atypical cerebriform-like ... Histopathological aspects and differential diagnosis of CD8 positive lymphomatoid papulosis.. Marschalkó M, Gyöngyösi N, Noll J ...
describe their experience with eight AA patients with lymphomatoid papulosis (LyP) and review similar cases. ... TagsLymphomatoid Papulosis, JDD case report, LyP, CD30+ T-cell lymphoproliferative disorder, dermatology case reports. Post ... Lymphomatoid papulosis (LyP) is a CD30+ T-cell lymphoproliferative disorder (LPD) presenting as a recurrent eruption of papules ... Lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (ALCL) comprise a disease spectrum known as ...
"Childhood lymphomatoid papulosis Type D, a rare and challenging diagnosis." Pediatr Dermatol, vol. 39, no. 6, Nov. 2022, pp. ... "Childhood lymphomatoid papulosis Type D, a rare and challenging diagnosis." Pediatr Dermatol 39, no. 6 (November 2022): 943-45 ... Childhood lymphomatoid papulosis Type D, a rare and challenging diagnosis.. Publication , Journal Article ... Brown DN, Blessing MM, Marcogliese AN, Vega F, Prose N, Metry D. Childhood lymphomatoid papulosis Type D, a rare and ...
A 47-year-old black man had typical papulonodular lesions of lymphomatoid papulosis (LyP) with concurrent plaque-stage mycosis ... Lymphomatoid Papulosis Associated With Plaque-Stage and Granulomatous Mycosis Fungoides. Jane L. Kardashian, MD; Herschel S. ... Lymphomatoid Papulosis Associated With Plaque-Stage and Granulomatous Mycosis Fungoides. Arch Dermatol. 1985;121(9):1175-1180. ... A 47-year-old black man had typical papulonodular lesions of lymphomatoid papulosis (LyP) with concurrent plaque-stage mycosis ...
Lymphomatoid papulosis. *Post-transplant lymphoproliferative disorder or PTLD. Please refer to our booklet, Non-Hodgkin ...
Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkins disease-associated antigens. ... Kadin M, Nasu K, Sako D, Said J, Vonderheid E. Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells ... Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkins disease-associated antigens ... Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkins disease-associated antigens ...
... lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.. Werner Kempf, Katrin Pfaltz, Maarten H Vermeer, ... are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous ...
Lymphomatoid papulosis. *Angioimmunoblastic T cell lymphoma. *Peripheral T cell lymphoma, unspecified. *Anaplastic large cell ...
Lymphomatoid papulosis and other lymphoproliferative disorders. *Ichthyoses and disorders of cornification. *Genodermatoses ...
Lymphomatoid papulosis is a self-healing recurrent popular eruption often exhibiting a chronic course. It is associated with ... Lymphomatoid Papulosis Associated with Recurrent Cutaneous T-Cell Lymphoma. AWH Tan, YC Giam ...
Lymphomatoid papulosis is a self-healing recurrent popular eruption often exhibiting a chronic course. It is associated with ... Lymphomatoid Papulosis Associated with Recurrent Cutaneous T-Cell Lymphoma. AWH Tan, YC Giam ...
Cancer: leukemia, lymphomatoid papulosis (LyP), lymphoma;. Reaction to Drugs/toxins: alcoholism, erythema nodosum, warfarin and ...
Achenbach, RE; Marina, S; S nchez, GF; Dutto, M. - Papulosis linfomatoide - Lymphomatoid papulosis. Rev. argent. dermatol; 96(1 ...
Categories: Lymphomatoid Papulosis Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, ...
... with lymphomatoid papulosis (LyP) at the benign end of the spectrum and primary cutaneous anaplastic large cell (PC-ALCL) ... lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011 Oct 13. 118 (15):4024-35. [QxMD ... Primary cutaneous CD30+ lymphoproliferative disorder (eg, primary cutaneous anaplastic large cell lymphoma, lymphomatoid ...
2018 - Lymphomatoid papulosis (non-reportable). 2020 - Transform to CTCL (and called Mycosis Fungoides specifically) (CTCL/MF ... Histology/Heme & Lymphoid Neoplasms--Mycosis Fungoides: What is the histology code for lymphomatoid papulosis that transforms ...
Localized lymphomatoid papulosis: Unilesional lymphomatoid papulosis, regional lymphomatoid papulosis, and persistent ... agmination of lymphomatoid papulosis. Magro CM, Mo JH, Telang G. Magro CM, et al. Among authors: mo jh. Clin Dermatol. 2022 Nov ...
Lymphomatoid papulosis is clinically benign, although clonal T-cell gene rearrangement can be demonstrated in 60-70% of cases. ... Lymphomatoid papulosis manifests as recurrent crops of self-healing, red-brown, centrally hemorrhagic or necrotic papules and ... Differentiation from lymphomatoid papulosis is not always possible based on histologic criteria. Immunologically, atypical ... The clinical picture and pathologic findings were consistent with lymphomatoid papulosis. This condition has a benign natural ...
Cancer: leukemia, lymphomatoid papulosis (LyP), lymphoma; Reaction to Drugs/toxins: alcoholism, erythema nodosum, warfarin and ...
Lymphomatoid papulosis in childhood with exclusive acral involvement. GJ Thomas, JS Conejo-Mir, AP Ruiz, ML Barrios, M ...
BACKGROUND: Lymphomatoid papulosis (LyP) is a benign recurrent papulonodular skin eruption with histologically malignant ... In search of prognostic indicators for lymphomatoid papulosis: a retrospective study of 123 patients.. J Am Acad Dermatol. 2012 ...
Angiodestructive lymphomatoid papulosis lasting more than 45years. JAAD case reports Lee, G. H., Bae, G. H., Rieger, K. E., Kim ...
Lymphomatoid Papulosis With a Unique T Follicular Helper-Like Phenotype (*Mentor of a Medical Student). Am J Dermatopathol. e- ... Lymphomatoid papulosis with DUSP22-IRF4 rearrangement: A case report and literature review. J Cutan Pathol. e-Pub 2023. PMID: ... The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis *Mentor of a Pathology resident. First place among ... CD8-positive CD30-positive lymphomatoid papulosis and its differential diagnosis: a review of 20 cases. J Cutan Pathol 39:99, ...
... including lymphomatoid papulosis) and melanoma. (1) ...
... lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011 Oct 13. 118 (15):4024-35. [Medline]. [ ...
  • A distinctive immunologic phenotype was demonstrated for the characteristic large atypical cells in the skin lesions of 9 patients with lymphomatoid papulosis (LP). Co-expression of Hodgkin's disease (HD)-associated antigen(s) Ki-1, and often Leu-M1, with helper T-cell antigens T11, T4, and T3 and cellular activation antigens Tac, Ia, and T9 was the most common phenotype, observed in 6 of 9 cases. (johnshopkins.edu)
  • Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis. (bvsalud.org)
  • Lymphomatoid papulosis (LyP) is a chronic papulonecrotic or papulonodular skin disease with histologic features suggestive of a malignant lymphoma. (medscape.com)
  • It classifies lymphomatoid papulosis as an indolent T-cell lymphoproliferative disorder of the skin, under primary cutaneous CD30 + T-cell lymphoproliferative disorders, along with primary cutaneous anaplastic large cell lymphoma (pcALCL). (medscape.com)
  • Lymphomatoid papulosis (LyP) is a recurrent, chronic, self-healing eruption that exists on a continuum with primary cutaneous anaplastic large cell lymphoma (C-ALCL). (logicalimages.com)
  • Lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (ALCL) comprise a disease spectrum known as primary cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ LPD). (nextstepsinderm.com)
  • EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. (qxmd.com)
  • Primary cutaneous CD30(+) lymphoproliferative disorders (CD30(+) LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. (qxmd.com)
  • In lymphomas I have conducted studies in rare aggressive primary cutaneous tumors such as gamma/delta T cell lymphoma (expanding the description of the epidermotropic variant) as well as more indolent entities such as lymphomatoid papulosis (type D) and CD4-positive small to medium size T cell lymphoproliferative disorders. (mdanderson.org)
  • In dermatology, LDH is characteristically part of the initial staging work-up of cutaneous lymphoma (including lymphomatoid papulosis) and melanoma. (aad.org)
  • However, the classification system for cutaneous lymphomas has evolved rapidly, and, during consensus meetings in 2003-2004, the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification grouped lymphomatoid papulosis among the indolent cutaneous T-cell lymphomas. (medscape.com)
  • In a 2005 study, the 30M377 allelic form of the CD30 promoter microsatellite repressive element was associated with the development of lymphomatoid papulosis, and the 30M362 allelic form was associated with progression to other CD30 + lymphomas in lymphomatoid papulosis patients. (medscape.com)
  • Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. (nih.gov)
  • Lymphomatoid papulosis/Other primary cutaneous lymphomas. (ejpd.com)
  • Lymphomatoid papulosis (LyP) is a disorder described by Macaulay in 1968 as a continuous self-healing, papular eruption, clinically benign and histologically malignant [ 1 ]. (cdlib.org)
  • Lymphomatoid papulosis (LyP) is a CD30+ T-cell lymphoproliferative disorder (LPD) presenting as a recurrent eruption of papules and nodules which resolve spontaneously. (nextstepsinderm.com)
  • A 47-year-old black man had typical papulonodular lesions of lymphomatoid papulosis (LyP) with concurrent plaque-stage mycosis fungoides (MF). (jamanetwork.com)
  • We examined the immune activation in 20 patients with mycosis fungoides, 6 patients with erythrodermia of unknown origin (Pré-Sézary's syndrome), 5 with lymphomatoid papulosis, 4 with parapsoriasis, 2 with Sézary's syndrome, and 2 with actinic reticuloid, by measuring soluble interleukin-2 receptor levels in serum. (medicaljournals.se)
  • Histopathological aspects and differential diagnosis of CD8 positive lymphomatoid papulosis. (nih.gov)
  • Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C". Arch Dermatol. (wikipedia.org)
  • [ 6 ] The 2016 classification described new subtypes of lymphomatoid papulosis with similar clinical behavior but atypical histologic/immunophenotypic features. (medscape.com)
  • Lymphomatoid papulosis is part of a spectrum of CD30 (Ki-1)-positive cutaneous lymphoproliferative diseases (CD30 + LPDs), including lymphomatoid papulosis, pcALCL, and borderline CD30 + lesions. (medscape.com)
  • Other events with a possible relation to TNF-α-blocking therapy included vasculitis, psoriasis, drug-induced systemic lupus erythematosus, dermatomyositis, and a lymphomatoid-papulosis-like eruption. (biomedcentral.com)
  • Scholars@Duke publication: Childhood lymphomatoid papulosis Type D, a rare and challenging diagnosis. (duke.edu)
  • Childhood lymphomatoid papulosis Type D, a rare and challenging diagnosis. (duke.edu)
  • A variant of lymphomatoid papulosis characterized by an epidermotropic infiltrate composed of small atypical cerebriform-like lymphocytes. (nih.gov)
  • Due to the typical waxing and waning clinical course, lymphomatoid papulosis was previously considered a pseuodolymphomatous inflammatory process. (medscape.com)
  • El-Darouti et al reported on a 7-year study of a hypopigmented disorder that the researchers believe should be classified as a new variant of parapsoriasis en plaque. (medscape.com)
  • We report a case of lymphomatoid papulosis (LyP) localized to the face. (cdlib.org)
  • The overall prevalence rate of lymphomatoid papulosis is estimated at at least 1.2 cases per 1,000,000 population. (wikipedia.org)
  • Spontaneous regression of lymphomatoid papulosis is seen almost universally, whereas regression occurs in approximately 25% of pcALCL cases. (medscape.com)
  • 2] Other cases have given rise to lymphomatoid papulosis. (medscape.com)
  • Lymphomatoid papulosis (LyP) is a rare skin disorder. (wikipedia.org)
  • Skin biopsy was consistent with lymphomatoid papulosis (LyP) Type D, a recently recognized subtype of LyP that is distinguished histologically by marked epidermotropism and a perivascular infiltrate of medium-sized pleomorphic lymphocytes with a cytotoxic phenotype (CD3+, CD8+). (duke.edu)
  • Cartas Cient ficas: Resultados a mediano plazo en el tratamiento endovascular del paciente claudicante / Scientific letters: Medium-term results in the endovascular treatment of claudicant patients. (bireme.br)
  • A rare case of ulcerative proctitis associated with type B lymphomatoid papulosis and superimposed human cytomegalovirus infection. (nih.gov)
  • The pathophysiology of CD30 + LPDs, including lymphomatoid papulosis (LyP), is largely unknown. (medscape.com)
  • Beljaards RC, Willemze R. The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. (medscape.com)
  • Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis. (medscape.com)
  • Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis. (bvsalud.org)
  • DUSP22-IRF4 rearrangements have been also reported in patients with lymphomatoid papulosis (LyP). (neogenomics.com)
  • Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea. (medscape.com)
  • EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. (medscape.com)
  • CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. (medscape.com)
  • 6. [Neutrophil-rich, anaplastic CD30+ T cell lymphoma in conjunction with lymphomatoid papulosis]. (nih.gov)
  • 16. Molecular evidence for a clonal relationship between lymphomatoid papulosis and Ki-1 positive large cell anaplastic lymphoma. (nih.gov)
  • 17. A comparison of clinical, morphological and immunohistochemical features of lymphomatoid papulosis and primary cutaneous CD30(Ki-1)-positive anaplastic large cell lymphoma. (nih.gov)
  • The excisional biopsy indicated that "The differential diagnosis includes lymphomatoid papulosis type C, primary cutaneous anaplastic large cell lymphoma, and skin involvement by systemic anaplastic large cell lymphoma. (cancer.org)
  • An unusual course was observed in a patient with indolent T-prolymphocytic leukaemia (T-PLL) who subsequently developed mycosis fungoides (Mf), lymphomatoid papulosis (LyP) and cutaneous CD30+ anaplastic large cell lymphoma (ALCL). (nih.gov)
  • Other types of CTCL include: lymphomatoid papulosis, peripheral T-cell lymphoma, cutaneous anaplastic large cell lymphoma, adult T-cell leukaemia /lymphoma, lymphomatoid granulomatosis, granulomatous slack skin disease, and pagetoid reticulosis, to name a few. (leukaemia.org.au)
  • Primary cutaneous CD30- positive large cell lymphoma (CD30+ PCLCL) represents a spectrum of disease, with lymphomatoid papulosis (LyP) at the benign end, and primary cutaneous anaplastic large cell lymphoma (PCALCL) at the other. (journalcra.com)
  • After a thorough clinicopathological correlation a diagnosis of CD30+PCLCL - lymphomatoid papulosis was made in first case and CD30+ PCLTCL - Anaplastic type in second. (journalcra.com)
  • Cutaneous CD30+ lymphoproliferative disorder (CD30+LPDs), including lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large-cell lymphoma (PCALCL), comprises the second most common group of cutaneous T cell lymphoma. (refine.bio)
  • 5. Pityriasis lichenoides et varioliformis acuta with numerous CD30(+) cells: a variant mimicking lymphomatoid papulosis and other cutaneous lymphomas. (nih.gov)
  • 11. CD30 antigen expression in cutaneous inflammatory infiltrates of scabies: a dynamic immunophenotypic pattern that should be distinguished from lymphomatoid papulosis. (nih.gov)
  • 12. CD8-positive lymphomatoid papulosis (type D): Some lesions may lack CD30 expression and overlap histologically with mycosis fungoides. (nih.gov)
  • 14. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins. (nih.gov)
  • Primary cutaneous Compact disc30-positive T-cell lymphoproliferative disorders (LPDs), which take into account 30% of cutaneous T-cell lymphomas (CTCLs), express CD30 always, aside from a uncommon subtype called type B lymphomatoid papulosis (LyP) [42]. (spierarchitecturalarts.com)
  • Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C". Arch Dermatol. (wikipedia.org)
  • To study the clinicopathologic characteristics and immunophenotype of lymphomatoid papulosis(LyP), followed by exon mutation analysis with focus on gene mutations involved in apoptosis pathway and other possible pathogenic genes. (nih.gov)
  • Regional lymphomatoid papulosis, type A. Int J Dermatol. (uchicago.edu)
  • It is not Mycosis Fungoides and it is closely related to Lymphomatoid Papulosis. (cancer.org)
  • Rajashekara Swamy M, Pollock S, J Goldberg L, Shen L. A case of lymphomatoid papulosis type E in a young adult: An uncommon entity. (bu.edu)
  • Lymphomatoid papulosis: an update and review. (medscape.com)
  • In search of prognostic indicators for lymphomatoid papulosis: A retrospective study of 123 patients. (medscape.com)
  • In the paper, the authors note that infections caused by Staphylococcus aureus, Bacillus anthracis, Borrelia burgdorferi, Sporothrix schenckii, the herpes zoster virus, and even lymphoproliferative conditions such as lymphomatoid papulosis have been misdiagnosed as bites from the spider Loxosceles recluse , commonly known as the Brown Recluse. (derm.city)